MODERN HEALTH OF AMERICA WORKS WITH MULTIPLE COMPOUNDING PHARMACIES THAT SHIP NATIONWIDE. CONTACT MODERN HEALTH OF AMERICA TODAY TO SCHEDULE YOUR COURTESY LABS
BHRT Weight Loss Programs
A new weight-loss drug that produced jaw-dropping clinical trial results in early 2021 may be the ammunition needed to get you to your weight loss goal. Semaglutide, an injectable drug already approved by the Food and Drug Administration as a treatment for Type 2 diabetes, produced moderate weight loss at its dose of 1 milligram weekly. Participants lost an average of 37 pounds through the combination of semaglutide and diet change.
“Semaglutide is part of a class of medications called GLP-1 receptor agonists, or glucagon-like peptide-1 receptor agonists. It increases insulin secretion, which is good for diabetes. But at higher doses, it acts on centers in the brain and suppresses appetite. It is important to use this medication in conjunction with lifestyle intervention. What this medicine does is help patients adhere to a reduced-calorie diet. With obesity, you always need lifestyle changes plus medicine.”
Should be used with a reduced calorie meal plan and increased physical activities. Semaglutide should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines. “You always have to consider nausea, vomiting, diarrhea, constipation” as potential side effects, he said. “But these are very manageable. Those tend to come on early in the course of treatment and get better over time. Only infrequently are they serious enough that patients have to stop taking the drug.
Semaglutide and Tirzepatide injections are FDA-approved GLP-1 agonist medications used to treat obesity and aid in dramatic weight loss. Semaglutide and Tirzepatide are both once-weekly injections that require no change in diet or lifestyle to produce weight loss results of greater than 50 lb in as little as 6 months. When used along with an individualized low-calorie, low-fat diet and exercise program to help with weight loss, overweight adults who may also have high blood pressure, diabetes, or high cholesterol see significant progress across all health markers. Semaglutide and Tirzepatide injections are a class of medications called glucagon-like-peptide-1 (GLP-1) agonists, although Tirzepatide has enhanced effects as a glucose-dependent insulinotropic polypeptide (GIP) agonist that produce more drastic weight loss results.